Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00730951 | The Evaluation and Standardization of Ginseng and Its Components for Blood Pressure Regulation | PHASE2 | COMPLETED | 18 | — | — | Jun 1, 2007 | Mar 1, 2008 | Jul 31, 2015 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 0.5g Korean Red Ginseng (1 capsule) 5.5g Corn Starch (11 capsules) |
| 2 | EXPERIMENTAL | 1g Korean Red Ginseng (2 capsules) 5g Corn Starch (10 capsules) |
| 3 | EXPERIMENTAL | 3g Korean Red Ginseng (6 capsules) 3g Corn Starch (6 capsules) |
| 4 | EXPERIMENTAL | 6g Korean Red Ginseng (12 capsules) |
| 5 | EXPERIMENTAL | 6g Corn Starch Control (12 capsules) |
| Name | Type | Description |
|---|---|---|
| Korean Red Ginseng | DIETARY_SUPPLEMENT | 500mg Capsulated Ground Dried Korean Red Ginseng Root |
| Corn Starch | DIETARY_SUPPLEMENT | 500mg Capsulated Corn Starch |
Inclusion Criteria: * Essential Hypertension Exclusion Criteria: * Secondary Hypertension * Diabetes * Chronic Kidney Disease * Liver Disease * Unstable Angina * Coronary / Cerebrovascular event in the previous 6 months